| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-04-24 | AstraZeneca (UK) Innate Pharma (France) | IPH2201, MEDI4736 | development |
Cancer - Oncology | Development agreement | |
| 2015-04-24 | AstraZeneca (UK) Celgene (USA - NJ) | MEDI4736 | non-Hodgkin’s lymphoma, myelodysplastic syndromes, multiple myeloma | development commercialisation |
Cancer - Oncology | Development agreement |
| 2015-04-24 | Immunogen (USA - MA) Sanofi (France) | coltuximab ravtansine (formerly SAR3419) | diffuse large B-cell lymphoma and other B-cell malignancies | product acquisition |
Cancer - Oncology | Product acquisition |
| 2015-04-24 | Bone Therapeutics (Belgium) | new headquarters at the Gosselies Biopark | opening of new premises | Bone diseases - Regenerative medicine | Opening of new premises | |
| 2015-04-23 | MRC Technology (UK) NYU School of Medicine (USA - NY) | antibody for the prevention of inflammatory osteolysis | prevention of inflammatory osteolysis | development |
Bone diseases | Development agreement |
| 2015-04-23 | Horizon Discovery (UK) Transgenomic (USA - NE) | MX-ICP technology | collaboration |
Technology - Services | Collaboration agreement | |
| 2015-04-23 | MedImmune (USA - global biologics arm of AstraZeneca (UK) Juno Therapeutics (USA - WA) | MEDI4736 and CD19-directed chimeric antigen receptor (CAR) T cell candidates | non-Hodgkin lymphoma | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-04-23 | Keryx Biopharmaceuticals (USA - NY) | nomination |
Renal diseases | Nomination | ||
| 2015-04-23 | apceth (Germany) | nomination |
Technology - Services | Nomination | ||
| 2015-04-22 | Vical (USA - CA) IPPOX Foundation (Switzerland) | HIV-antigen plasmid DNA | HIV - AIDS | production manufacturing |
Infectious diseases | Production agreement |
| 2015-04-22 | Ligand Pharmaceuticals (USA - CA) Sage Therapeutics (USA - MA) | SAGE-547 | super-refractory status epilepticus (SRSE) | milestone |
CNS diseases - Neurological diseases | Milestone |
| 2015-04-22 | Aveo Oncology (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-04-22 | Sygnis (Germany) | nomination |
Nomination | |||
| 2015-04-22 | Genvec (USA - MD) | nomination |
Nomination | |||
| 2015-04-21 | MaxCyte (USA - MD) Johns Hopkins University (USA - MD) | CAR T-cell therapies | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-04-21 | Affectis Pharmaceuticals (Germany) The Lead Discovery Center (LDC) (Germany) Charcot-Marie-Tooth Association (CMTA) (USA -IL) | small molecule antagonists of the P2X7 ligand-gated ion channel | Charcot-Marie-Tooth (CMT) disease type 1A (CMT1A) | collaboration | Rare diseases - Genetic diseases - Neurological diseases | Collaboration agreement |
| 2015-04-21 | Quest Diagnostics (USA - NY) Inserm (France) Inserm Transfert (France) | BRCA Share™ | breast cancer, ovarian cancer | collaboration |
Cancer - Oncology - Technology - Services | Collaboration agreement |
| 2015-04-21 | Audentes Therapeutics (USA - CA) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2015-04-21 | Genvec (USA - MD) Laboratory of Malaria Immunology and Vaccinology (LMIV) (USA) | malaria vaccine candidates | malaria | collaboration R&D |
Infectious diseases - Parasitic diseases | Collaboration agreement |
| 2015-04-20 | NeoStem (USA - NY) Kite Pharma (USA - CA) | development and manufacturing services for Kite\'s lead eACT™ clinical development program | services contract |
Technology - Services - Cancer - Oncology | Services contract |
